A Phase 2 interventional study of Bortezomib in Neuromyelitis Optica Spectrum Disorder, sponsored by Tianjin Medical University General Hospital. Completed at 1 site in China. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-04-11.
Sponsored by Tianjin Medical University General Hospital · Phase 2, Interventional, and Treatment
Neuromyelitis Optica Spectrum Disorders (NMOSD) is characterized by the pathogenic anti-AQP4 antibody, which can be produced by specific plasma cells. The patients who are not responsive to rituximab treatment may be due to the presence of short-lived and long-lived plasma cells. Previous studies confirmed that the proteasome inhibitor bortezomib (Velcade®, approved for therapy of multiple myeloma) eliminated both plasmablasts and plasma cells by activation of the terminal unfolded protein response. Treatment with bortezomib may help deplete plasma cells producing auto-antibodies. Therefore, the rationale for using bortezomib in NMOSD is in that bortezomib may help eliminate autoreactive plasma cells and reduce anti-AQP4 antibodies titers. It is noted that bortezomib may protect astrocytes from NFκB-dependent inflammatory damage in early events in NMOSD pathogenesis.
The purpose of this study is to determine if the drug bortezomib contributes to reduce the average relapsing rates (ARRs) and alleviate neurological disability in NMOSD patients.
It has been shown in some scientific studies that the the antibody marker specific for neuromyelitis optica spectrum disorders (NMOSD), known as AQP4-IgG, causes inflammation in brain tissues by activating NF-κB pathway. Bortezomib has already been shown to be effective in systemic lupus erythematosus (SLE).
The overall objective is to assess the efficacy and safety of bortezomib as add-on therapy to oral steroids,azathioprine or others for treatment of relapsing NMOSD, which have not reduced average relapsing rate (ARR) effectively.
The primary (most important) objectives of this study are to determine:
Whether bortezomib reduces relapse frequency in patients with relapsing NMO. The number of attacks during the one year treatment period will be compared to the number of attacks that occurred prior to initiation of bortezomib treatment.
The secondary objectives are to determine:
The safety profile of bortezomib in patients with NMO. Whether bortezomib maintains or improves walking, visual function and quality of life as measured by a variety of established disability scales. We will also assess the severity of an individual attack and the degree of recovery.
Depending on our preliminary investigations we may evaluate patient cerebrospinal fluid in the laboratory to see how effective eculizumab is at getting into the cerebrospinal fluid from the blood stream, and to see if the drug reverses the biological effects of the NMO-IgG antibody.
168 studies on the registry are indexed under Neuromyelitis Optica; 72 are open to participants now.
This study's enrollment of 5 is below the median of 26 across 100 interventional studies indexed under Neuromyelitis Optica.
Browse Neuromyelitis Optica studies →Tianjin Medical University General Hospital is the lead sponsor of 74 studies on the registry; 30 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
A proteasome inhibitor
Drug: Bortezomib
Bortezomib will be subcutaneously applicated in 4 treatment cycles with 4 injections of 1 mg Bortezomib /m2 body surface per cycle
Also known as: Velcade
Annual relapse rate (ARR) of NMOSD Attacks
Compare annual relapse rate before and one year after initial Bortezomib administration
Time frame: Baseline, after 12 months of initial treatment
Number of Participants with Adverse Events
All adverse events and side effects related to this drug will be recorded
Time frame: Baseline, 12 months
Change in Expanded Disability Status Scale (EDDS) Score
The EDSS is an ordinal clinical rating scale ranging from 0 (normal neurologic examination) to 10 (death) in half-point increments.
Time frame: Baseline, 12 months
Timed 25-foot Walk
The Timed 25-Foot Walk test is a quantitative measure of lower extremity function
Time frame: Baseline, 12 months
Number of Subjects With Change in Visual Acuity in at Least One Eye by at Least One Point
Visual acuity was measured using the the visual acuity subscale of the opticospinal impairment score (OSIS) for Exacerbations. This subscale ranges from 0 (normal) to 8 (no light perception).
Time frame: Baseline, 12 months
MRI brain and spine
MRIs will be analyzed for counting the numbers of new lesions by T2 hyper-intensity in the brain, spinal cord and optic nerve (minimal number is 0), and the volume of T1 post-contrast enhancement (minimal volume is 0 cm3).
Time frame: Baseline, 12 months
Retinal nerve fiber layer (RNFL)
Compared RNFL before and one year after initial Bortezomib administration
Time frame: Baseline, 12 months
Cognition
Compare cognition questionnaire scale before and one year after initial Bortezomib administration
Time frame: Baseline, 12 months
Immunological assessments
Compare Ig subclasses (serum IgG1,IgG2, IgG3 and IgG4 concentrations by mg/dL), anti-aquaporin4-ab (measured by FIPA nmol/L and FACS assay titre), cytokine kinetics (measured by ELISA assay titre), relevant plasma cells depletion (number of circulating cells measured by count/μL ) before and one year after initial Bortezomib administration
Time frame: Baseline, 12 months
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bortezomib
Tianjin Medical University General Hospital